![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 20, 14958-14963, May 19, 2000
,From the Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York 10010
| |
ABSTRACT |
|---|
|
|
|---|
We previously reported that
S-adenosylmethionine (AdoMet), a key molecule in
methylation reactions and polyamine biosynthesis, enhances axenic
culture of the AIDS-associated opportunistic fungal pathogen
Pneumocystis carinii. Here we report that AdoMet is
absolutely required for continuous growth. Two transporters are
present, one high affinity, Km = 4.5 µM, and one low affinity, Km = 333 µM. The physiologically relevant high affinity transporter has a pH optimum of 7.5 and no related natural compounds compete for uptake. Transport is 98% inhibited at 4 °C, 24%
inhibited by 20 mM sodium azide, and 95% inhibited by the
combination of 20 mM sodium azide and 1 mM
salicylhydroxamic acid; thus transport is active and dependent on both
a cytochrome chain and an alternative oxidase. In vitro,
AdoMet is used at a rate of 1.40 × 107 molecules
cell Pneumocystis carinii is a fungus that causes P. carinii pneumonia (PCP)1
in people with AIDS, patients undergoing cancer chemotherapy, and
others with conditions causing severe immunosuppression. Although the
frequency of PCP in HIV-infected persons has decreased dramatically over the last 8 years, due first to widespread prophylaxis against PCP
and more recently to the reduced immunosuppression brought on by
improved anti-HIV therapy, PCP remains common in AIDS patients. Treatment for PCP is less than ideal with frequent severe side effects
from the two most effective drugs, pentamidine and the combination of
trimethoprim and sulfamethoxazole (cotrimoxazole, TMP-SMZ) (1). The
mortality rate also remains high (21.5%) (2). Beyond the importance of
P. carinii as a pathogen, it is also an unusual and
interesting fungus for which most basic metabolic processes are unknown.
S-Adenosyl-L-methionine (AdoMet) plays a pivotal
role in the physiology of all cells, both as methyl donor in myriad of
biological and biochemical events and as a precursor of polyamines.
About 95% of AdoMet is used for transmethylation reactions in which the N-methyl group of the methionine moiety is transferred
to large molecules such as proteins, complex lipids, and DNA or to small molecules to form lecithin, regenerate methionine, etc. (3). The
remaining 2-5% of AdoMet is decarboxylated to become the aminopropyl
donor for synthesis of the essential polyamines spermidine and spermine
(4). Transmethylation reactions result in the formation of
S-adenosylhomocysteine which is then hydrolyzed by
S-adenosylhomocysteine hydrolase to form adenosine and
homocysteine. Decarboxylation of AdoMet is catalyzed by
S-adenosylmethionine decarboxylase producing decarboxylated
AdoMet, an intermediate committed to polyamine biosynthesis.
Decarboxylated AdoMet donates an aminopropyl group to putrescine to
form spermidine or to spermidine to form spermine. The end product of
the aminopropyl transfer reactions is methylthioadenosine which is
cleaved by a specific phosphorylase, the products being recycled in
various ways to methionine and purines, respectively. A comprehensive
review of polyamine metabolism and function has been published (3).
AdoMet is synthesized by AdoMet synthetase which transfers the adenosyl
group of ATP to methionine with the residual triphosphate being
hydrolyzed to Pi and PPi by the polyphosphatase
activity of AdoMet synthetase. To our knowledge, with the exception of mutants, no cell has previously been reported to lack this enzyme and
AdoMet has not been known to be an essential nutrient. That AdoMet is
an essential metabolite is shown by a mutant of Escherichia coli with very low AdoMet synthetase activity resulting in a cell division defect (4) and by knockout of this enzyme in
Saccharomyces cerevisiae which is lethal but death can be
prevented by exogenous AdoMet (5). Despite the universal activity of
AdoMet synthetase, exogenous AdoMet can have an effect on wild type
cells. For example, added AdoMet can stimulate budding and outgrowth as
well as RNA and protein synthesis in S. cerevisiae (6).
Another example is patients recovering from liver cirrhosis which
results in low AdoMet synthetase activity; these patients are benefited
by supplementing their diet with AdoMet (7, 8). Since AdoMet has been
reported to enhance growth of another fungus (6), we added AdoMet to the medium we used to develop an axenic culture for P. carinii. This caused a qualitative and quantitative improvement in
P. carinii culture including the production of cysts.
Because of the positive effect of AdoMet on axenic culture of P. carinii culture and because analogues of AdoMet have been explored
as pharmaceutical leads, we examined P. carinii for the
possibility of an AdoMet requirement, for the ability to transport of
AdoMet, for the rate of use of AdoMet and for the capacity to
synthesize this essential intermediate. We found that P. carinii has a transport system for AdoMet which seems completely
AdoMet-specific. We also found that P. carinii is an AdoMet
auxotroph, a condition not previously reported for any cell.
Chemicals--
[methyl-14C]AdoMet was
purchased from Moravek Biochemicals Inc. (Brea, CA).
[methyl-14C]Methionine was from Amersham Life
Science (Burkinghamshire, United Kingdom). Ultra-pure AdoMet was
purchased from Research Biochemical International (Natick, MA).
Putrescine, ferric pyrophosphate, L-cysteine, glutamine,
L-methionine, ATP, hypoxanthine, adenine, di-sodium
phosphate, monopotassium phosphate, sodium chloride, trisodium citrate,
dithiothreitol, potassium chloride,
S-adenosyl-L-homocysteine, dibutyl phthalate,
acetonitrile, perchloric acid, heptane sulfonic acid,
S-adenosyl-L-methionine, KCl, HEPES,
MgSO4, 1,7-diaminoheptane, and methylthioadenosine were
from Sigma. AccQ.Fluor reagent kit was from Waters Corp. (Milford, MA).
Culture of P. carinii--
In vitro axenic culture of
P. carinii was as described previously (9). Briefly,
P. carinii cells were maintained in medium consisting of
minimum essential medium with Earle's salts (Life Sciences, Grand
Island, NY) supplemented with 20% horse serum (Life Sciences), and 80 µg ml Rat Model of PCP--
Rats were treated with antibiotics to
limit other potential opportunistic infections, immunosuppressed then
intratrachealy inoculated with P. carinii as described
previously (11). Twenty-two days after inoculation, the rats were
sacrificed. Lungs and blood were collected, processed, and P. carinii quantitated as described previously (12). The lungs and
plasma were then stored in liquid nitrogen for up to 4 years. The
thawed samples were analyzed for AdoMet content using a method
depending on detection of a fluorescent adduct as described below.
Transport Measurement--
For uptake studies a previously
published method (13) was modified. Cultured P. carinii
cells were washed three times with MEM and resuspended in SPB at a
density of approximately 7 × 107 cells
ml AdoMet Analysis--
A new method based on reverse phase
ion-pair chromatography was developed for quantitation of AdoMet in
P. carinii culture medium. An 80-µl medium sample from a
P. carinii culture or control medium, held under the same
conditions but without AdoMet or serum added, was mixed with 20 µl of
10% perchloric acid. After centrifugation at 5000 × g
for 5 min to remove precipitated material, the supernatants were
collected for HPLC assay. An internal standard, S-adenosyl ethionine (SAE), was added to all samples to a concentration of 13.9 µM. Chromatographic separation was achieved with an octyl silanol (C8) reverse phase column (3.9 × 150 mm,
Rainin Instrument Co., Woburn, MA) using an isocratic mobile phase of
40 mM ammonium phosphate, 8 mM heptane sulfonic
acid (ion pairing reagent), and 3.6% acetonitrile (pH 5.0). The
injection volume was 70 µl and the flow rate was 1.0 ml
min
An alternative method was used for measuring AdoMet in rat plasma
samples. AdoMet was extracted from plasma exactly as above. Pre-column
derivitization was performed as described previously for polyamine
analysis (14). An internal standard of 5 µl (5 µg ml Measurement of AdoMet Synthetase Activity--
Preparation of
dialyzed P. carinii extract for enzymatic analysis was as
described previously (15). Enzyme assay conditions were adapted from a
published method (16). Enzymatically produced AdoMet was measured by
HPLC with detection either by UV absorbance as described above or by
measurement of radiolabeled methionine incorporated into AdoMet using a
radioactivity detector with a 300-µl solid scintillant flow cell
(Radiomatic Series A100, Packard Instruments, Downs Groove, IL). Rat
liver extract was used as a known source of AdoMet to validate the
enzyme assay. When UV detection was used, the final reaction mixture
included 150 mM KCl, 2 mM dithiothreitol, 25 mM HEPES, 500 µM ATP, 5 mM
MgSO4, 1 mM methionine in a final volume of 200 µl of which 150 µl was crude dialyzed extract. Reactions were
terminated by adding 40 µl of 10 N perchloric acid and
placing the mixture on ice. When AdoMet was detected by radiolabel, the
assay mixture was the same except that except that 400 µM
[methyl-14C]methionine was used and the final
volume of the reaction mixture was 100 µl of which 90 µl was the
crude extract.
Protein Assay--
An aliquot of cells from each experiment was
retained to determine protein concentration (dotMetric assay, Geno
Technology, Inc., St. Louis, MO) and the remaining cells were used
immediately for various experiments.
Utilization of AdoMet from the Medium--
Using authentic AdoMet,
a novel HPLC analytical method based on UV absorbance was developed,
calibrated, and validated. The assay was shown to be linear
(r > 0.99) and sensitive to the picomole range (data
not shown). Fig. 1 presents AdoMet
decline in culture medium over 19 h with and without cells. The
decline without cells is due to spontaneous degradation due to high pH
(8.8-9.2) as previously reported (17). The greater decline in the
presence of cells represents AdoMet utilization by P. carinii. Based on the 101 µM difference in AdoMet
concentration after 8 h with 9.0 × 106 P. carinii cells ml Effect of AdoMet on Growth of P. carinii--
Growth of P. carinii in culture with and without the addition of 500 µM AdoMet was followed for 27 days (Fig.
2A). After 15 days the number
of cells in cultures without AdoMet began to decline and at 27 days
they were only 22% of the number in cultures to which AdoMet had been
added. This experiment was repeated (Fig. 2B) and the
utilization of AdoMet was followed as the cell numbers increased. At
each time point in Fig. 2B, the AdoMet content of the medium
was measured at the time the cells were harvested for counting; these
harvests were always 12 h after the addition of fresh medium and
fresh AdoMet. The AdoMet remaining in the medium declined linearly with
the increase in cell number (r > 0.90). Overall the
pattern of growth is similar in Fig. 2, A and B,
with the number of cells first increasing then declining in the
cultures without AdoMet. Omission of AdoMet not only reduced the total number of P. carinii cells in culture but the cells were
limited to small trophozoites rather than the mixture of small
trophozoites, large trophozoites, and cysts seen in cultures grown with
AdoMet or isolated from infected lungs (Giemsa-stained smears, data not shown). Since there was some P. carinii growth even without
added AdoMet, we examined the possibility that this was dependent on AdoMet in the horse serum component of the medium. Two lots of horse
serum were analyzed and the mean AdoMet content was 32 ± 2 µM. In two lots of fetal bovine serum, the serum
supplement most commonly used for tissue culture medium, the mean
AdoMet was 0.62 ± 0.15 µM. Growth of P. carinii was compared in media made with 20% dialyzed horse serum
(Fig. 2C) and 20% fetal calf serum (Fig. 2D),
both with and without the addition of AdoMet. Dialysis reduced the
AdoMet content of horse serum to less than 2 nM. After 21 days in culture, the cells grown in media without additional AdoMet
contained only 2% of the number of cells in media with added AdoMet.
We also followed utilization of AdoMet from the media to which this
metabolite was added and the AdoMet remaining at each time point was
inversely linearly correlated with the number of cells in culture
(r > 0.90).
S-Adenosylmethionine Transport--
To determine the extent of
AdoMet uptake, P. carinii cells were incubated for different
times in SPB buffer containing 33 µM
[14CH3]AdoMet and AdoMet incorporated into
the cells measured as described under "Experimental Procedures."
The results shown in Fig. 3 indicate
that, under these conditions, AdoMet accumulates in the cells reaching
a maximal concentration at 2 min. To be sure that radioactivity
measured in the cells represented AdoMet uptake rather than uptake of a
breakdown product, P. carinii cells incubated with labeled
AdoMet for 30 s were lysed and analyzed by HPLC. The only
radioactive peak was at the AdoMet retention time confirming that the
radioactivity measured in the cells pellets did represent transported
AdoMet. Transport of AdoMet into P. carinii was measured
over a range of pH values (4.0 to 8.5) using SPB buffer. Incubations
were for 120 s and the [14CH3]AdoMet
concentration was 33 µM. Transport was pH dependent with
a sharp optimum at pH 7.5. To determine transport kinetic constants,
P. carinii cells were incubated for 30 s in the
presence of various concentrations of
[14CH3]AdoMet. The Lineweaver-Burk plots
shown in Fig. 4 indicate the presence of
two transporters. For the high affinity transporter a
Km value (4.45 µM) was calculated and
the extrapolated Vmax value was 22 nmol
min AdoMet Biosynthesis--
The effect of exogenous AdoMet on growth
of P. carinii in axenic culture and the existence of a
specific AdoMet transporter suggested that P. carinii may
not be able to synthesize AdoMet and thus be dependent on the host for
this metabolite. For conclusive evidence, we examined P. carinii for the presence of AdoMet synthetase, the sole enzyme
required for AdoMet biosynthesis from ATP and methionine. Rat liver
homogenate supernatant was used as a known source of activity to
validate the assay. UV detection of AdoMet and a 15-min reaction time
were used. Using this assay, the activity of rat liver was 68.3 ± 7.5 pmol of AdoMet synthesized min AdoMet Use in Vivo--
Having shown that AdoMet is required by
P. carinii and is depleted from culture medium, we
considered the possibility that P. carinii might cause a
reduction in the plasma AdoMet concentration in infected animals.
Concentrations of most plasma components are held relatively constant
by a negative feedback system but since individual cells all synthesize
AdoMet, we thought it possible that AdoMet could be an exception so
that an increase in utilization from the plasma would be reflected by a
decrease in the plasma concentration. We were correct as shown in Fig.
6 which presents the plasma AdoMet
concentrations of individual rats plotted against the number of
P. carinii in the lungs. The negative relationship is
striking. This result also indicates that the requirement for AdoMet is
not a culture artifact.
AdoMet is an essential intermediate in the physiology of the cell,
both for synthesis of polyamines and as a methyl donor for nearly all
methylation reactions (3). To our knowledge, all cells investigated
previously were found able to synthesize this intermediate from ATP and
methionine using the enzyme AdoMet synthetase; AdoMet has never been
described as an essential nutrient. To understand the reason underlying
our previous observation that adding AdoMet to culture medium
qualitatively promotes P. carinii growth (9) and to expand
our general investigation of P. carinii polyamine metabolism
(10, 15, 20, 21), we examined P. carinii both for the
ability to utilize exogenous AdoMet and to synthesize this compound
de novo. The results indicate that P. carinii has
an absolute need for AdoMet and to date is the only cell known to be a
natural AdoMet auxotroph.
The data reported here demonstrate the degree to which AdoMet both
maintains and increases P. carinii growth in
vitro. It is interesting to note that in the cultures with whole
horse serum but without AdoMet, the initial growth followed by a slow
decline is reminiscent of the growth in culture systems described prior to our recently published axenic system (9). Previous culture systems
(22) utilized a mammalian feeder cell and very likely these cells
provide a significant but limited amount of AdoMet. A similar role is
played by the high concentration of AdoMet in horse serum relative to
the more frequently used fetal calf serum. One could speculate that
addition of AdoMet to a culture system using mammalian cells would
allow continuous passage to fresh feeder cells. We were able to confirm
AdoMet utilization by showing that P. carinii causes
depletion of this metabolite from the growth medium and this is nicely
supported by the in vivo data showing that P. carinii infection causes rat plasma to become depleted of AdoMet.
Although our initial culture medium contained 500 µM AdoMet and this concentration was used for the studies reported here,
we have found that 50 µM AdoMet is adequate to support
growth. Starting at 50 µM, the spontaneous rate of AdoMet
degradation in the medium predicts a decline to 14 µM or
5.6 µg ml Kinetics of AdoMet uptake indicate the presence of a transporter and
the effect of metabolic inhibitors indicate that transport is an
active, energy-requiring process. One of the most interesting kinetic
findings was with natural compounds related to AdoMet none of which
competed with AdoMet for transport. These compounds include:
L-methionine and ATP (the components of AdoMet),
hypoxanthine (a purine frequently scavenged by cells), adenine (the
purine moiety of AdoMet), S-adenosylhomocysteine (AdoMet
missing the S-methyl group), decarboxylated AdoMet (AdoMet missing the
carboxyl group of methionine), methylthioadenosine (AdoMet after
decarboxylation and donation of a propyl group), and
S-adenosylethionine (an analogue with the
S-methyl group substituted by an S-ethyl group).
Therefore, it seems that the transporter recognizes neither any
component of AdoMet nor any physiologically modified AdoMet suggesting
that this transporter may recognize AdoMet alone. AdoMet transport by
S. cerevisiae is similar to P. carinii in being
facilitated by a high affinity transporter which is pH and energy
dependent with a similar Km (3.3 µM)
(24). However, this S. cerevisiae transporter is not
strictly AdoMet specific since both S-adenosylhomocysteine and S-adenosylethionine can compete with AdoMet although
adenosine, methionine, and homocysteine do not (24). A recent study
(18) reported an additional transport system in S. cerevisiae as well as cloning the originally described
transporter. The originally described transporter is coded by the SAM3
gene and shows homology to the family of amino acid transporters. The
newly described transporter is of low affinity (Km = 160 µM), operates by facilitated diffusion and is not
able to supply the needs of the cell fully, even at high concentrations
of AdoMet. We also detected a second transport system in P. carinii but with a Km = 330 µM it
cannot be physiologically significant. It seems likely that the low
affinity transporter activity is due to an entirely different
transporter that will recognize AdoMet when it is at very high,
non-physiological concentrations. The AdoMet transporter of African
trypanosomes is as specific for AdoMet as the P. carinii transporter, although it operates by facilitated diffusion rather than
active transport (25). In mammalian cells AdoMet penetrates poorly and
extracellular AdoMet is mainly utilized to methylate phospholipids on
the surface of plasma membrane (26).
The effect of metabolic inhibitors on AdoMet transport suggest that
P. carinii utilizes both a cytochrome-mediated electron transport system and alternative oxidase-mediated system for energy production. Azide, which blocked transport by 24%, is a standard inhibitor of cytochrome-mediated ATP production. Salicylhydroxamic acid, which in combination with azide blocked transport by 95%, inhibits the enzyme alternative oxidase which provides a branch in
electron transport at the level of ubiquinol. Although alternative oxidase itself does not lead to ATP generation by pumping protons, it
does support transport of electrons to molecular oxygen, thus allowing
ATP generation based on site 1 of oxidative phosphorylation as well as
substrate level phosphorylation in the mitochondrion (27). Using an
oxygen electrode, we have directly observed the ability of
salicylhydroxamic acid to inhibit oxygen consumption (data not shown).
We conclude that P. carinii is an AdoMet auxotroph for the
following reasons. AdoMet is necessary to support growth in
vitro. P. carinii causes depletion of AdoMet from the
culture medium. P. carinii has an AdoMet-specific
transporter and no AdoMet synthetase activity. Strong evidence that
these are not in vitro artifacts is provided by the finding
that the concentration of AdoMet in rat plasma declines in proportion
to the degree of P. carinii infection. An excellent
chemotherapeutic opportunity is presented by this dependence of
P. carinii on exogenous AdoMet and the presence of a
specific transporter as well as the fact that mammalian cells do not
transport AdoMet well. Although normal metabolites related to AdoMet do
not inhibit transport, it may be possible to design analogues that are
recognized by the transporter with equal or greater affinity than
AdoMet. If transported in place of AdoMet, such compounds can also be
expected to interfere with AdoMet-dependent methylation and
with polyamine biosynthesis. This dual mode of action would be
synergistic because suppression of AdoMet transport will increase the
ratio of analogue to AdoMet within P. carinii thus enhancing
the effect of the analogue on AdoMet utilizing enzymes. Because
mammalian cells do not actively transport AdoMet, the chances of
developing a compound with high specificity of P. carinii
are good. Analogues of AdoMet have already been synthesized and
considered as pharmaceutical leads for other infectious agents (28); a
compound useful as an anti-P. carinii agent may be among these.
1 min
1. AdoMet synthetase activity was
not detected by a sensitive radiolabel incorporation assay capable of
detecting 0.1% of the activity in rat liver. In addition, the AdoMet
plasma concentration of rats is inversely correlated with the number of
P. carinii in the lungs. These findings demonstrate that
P. carinii is an AdoMet auxotroph. The uptake and
metabolism of this compound are rational chemotherapeutic targets.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 of each of the following: putrescine, ferric
pyrophosphate, L-cysteine, and glutamine (PcMEM). Inocula
(1.5 ml) containing 3 × 106 cells ml
1
were placed in 24-mm collagen-coated, 0.4-µm membrane pore size TranswellR inserts held in 6-well plates (Corning Costar
Corp.). An additional 2.5 ml of medium was added to the wells below the
inserts. The Transwell system allows changes of medium below the insert
without disturbance of the cells within the inserts. The medium was
changed twice daily and at each change freshly prepared 10 mM AdoMet stock solution was added to yield a final
concentration of 500 µM. Cultures were incubated at
31 °C in room temperature. For counting, cells in the inserts were
suspended by agitation and 10-µl samples were removed and diluted
10-fold with the following buffer: 58.5 mM disodium
phosphate, 1.5 mM monopotassium phosphate, 43.5 mM NaCl, 10 mM trisodium citrate, 10 mM dithiothreitol, and 2.7 mM KCl, pH 7.4 (SPB). Citrate and dithiothreitol were included to help dissociate
clumps of P. carinii thus facilitating counting
Giemsa-stained smears as described previously (10). For some cultures
growth was monitored by measuring total DNA in the culture as described (9).
1. Each assay had a final volume of 50 µl which
included 45 µl of P. carinii cell suspension and an
appropriate amount of [14CH3]AdoMet
supplemented with any other test compound in 5 µl of SPB buffer.
After a suitable incubation time at 37 °C,
[14CH3]AdoMet remaining in the incubation
medium was separated from the cells by microfuging through 100 µl of
dibutyl phthalate and mineral oil (1:1). The supernatants were
discarded and the cell pellets were collected and counted by liquid scintillation.
1. Absorbance was detected by a photodiode array
(Waters 996) and recorded at 1-nm intervals from 200 to 500 nm.
Chromatograms were extracted at 257 nm. Absorbance data at wavelengths
other than 257 nm were used for MillenniumTM (Waters Corp.,
Milford, MA) software peak purity algorithms and for three-dimensional
computer displays which were helpful for initial method development.
1
of 1,7-diaminoheptane) and 45 µl of borate buffer (0.2 M
sodium borate, 1 mM EDTA, pH 8.8) was added to 30 µl of
clarified plasma. After mixing, 20 µl of AccQ.Fluor reagent was
added. HPLC conditions were as described previously for polyamine
analysis (14). This method was calibrated and validated by
demonstrating linearity (r > 0.99) and sensitivity in
the subpicomole range using purchased authentic AdoMet.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 and without cells, AdoMet usage
calculates to be 1.40 × 107 molecules
cell
1 min
1.

View larger version (10K):
[in a new window]
Fig. 1.
Utilization of AdoMet by P. carinii in culture. The difference between medium with
P. carinii and medium without represents AdoMet utilization
by P. carinii. Data points are mean (±S.D.) from three
independent experiments.

View larger version (20K):
[in a new window]
Fig. 2.
Effect of AdoMet on P. carinii
growth in medium containing horse serum, dialyzed horse serum,
and fetal bovine serum. For panel A growth was
monitored by counting cells in Giemsa-stained slides. For panels
B, C, and D, growth was monitored by a DNA analysis
method (9). The medium used for panels A and B
used horse serum which has a relatively high natural AdoMet content (32 µM), panel C contained dialyzed horse serum
(<2 nM AdoMet), and panel D, fetal calf serum
which has a low content of AdoMet (0.62 µM AdoMet). The
numbers on top of the curves in panels B,
C, and D are AdoMet concentrations of the medium at the
time the cells were harvested for counting; these harvests were always
12 h after the addition of fresh medium and AdoMet; the AdoMet
remaining after 12 h declines as the number of P. carinii cells increases. Compared with growth in a medium
containing horse serum which has a naturally high AdoMet content, the
effect of the addition of AdoMet to the culture medium is greater when
the serum component of the culture medium is either dialyzed horse
serum or non-dialyzed fetal calf serum which has a lower AdoMet
concentration than horse serum.
1 mg of protein
1. For the low affinity
transporter the Km is 333 µM and the
Vmax 476 nmol min
1 mg of
protein
1. Further studies were done with only the high
affinity transporter because AdoMet concentrations in vivo
are never high enough for the low affinity transporter to be
physiologically relevant. This situation is similar to S. cerevisiae which has both a high and low affinity transporter
(18). To detect whether AdoMet uptake was by facilitated diffusion or
by active transport, inhibitors were used to block the production of
ATP which would be required for active transport. The cytochrome
inhibitor sodium azide (20 mM) reduced transport by 24 ± 4% (n = 3), however, the combination of the
alternative oxidase inhibitor salicylhydroxamic acid (1 mM)
and sodium azide (20 mM) reduced AdoMet transport by
95 ± 3% (n = 3). When cells were held on ice,
uptake was 2% of that at 37 °C. Thus AdoMet is actively
transported. Specificity of this AdoMet transporter was examined by
testing the ability of compounds closely related to AdoMet to compete
with AdoMet transport. The compounds listed in Table
I were added to cell suspensions at the
same 33 µM concentration as
[14CH3]AdoMet. The data show that none of
these related compounds inhibited
[14CH3]AdoMet uptake. Unlabeled AdoMet did
compete as expected.

View larger version (6K):
[in a new window]
Fig. 3.
Accumulation of AdoMet by P. carinii. Uptake was measured using AdoMet at 33 µM and conditions as described under "Results." Data
points are mean (±S.D.) from three independent experiments. AdoMet
accumulation is linear for 60 s.

View larger version (12K):
[in a new window]
Fig. 4.
Lineweaver-Burk plot of AdoMet
transport. Incubations for transport were for 30 s and AdoMet
concentrations ranged from 0.1 to 200 µM. The upper
regression line in panel A was calculated from data
points relevant to the high affinity transporter (2-15
µM AdoMet). The lower regression line in
panel A is the same as the regression line in panel
B and was calculated from data points relevant to the low affinity
transporter (50-300 µM AdoMet).
Competition with [14CH3]AdoMet transport
1 mg of
protein
1, comparable to a reported value of 73.2 ± 9.6 pmol min
1 mg of protein
1 (19). P. carinii activity was below the detectable level of 1 pmol
min
1 mg of protein
1. The assay was repeated
with radiolabeled methionine using a reaction time increased to 30 min
but this produced no radioactivity at the retention time for AdoMet
(top panel of Fig. 5). To
demonstrate the ability to detect very small amounts of radiolabeled
AdoMet, 20 pmol of authentic radiolabeled AdoMet was added to the same incubation mixture producing the peak with a 15-min retention time seen
in the bottom panel of Fig. 5. If an equal amount of liver
homogenate had been used for the same incubation time, calculations indicate that 455 pmol of AdoMet would have been produced. Inspection of the chromatogram spiked with labeled AdoMet shows that this method
could easily detect 0.5 pmol of AdoMet. Based on this, the AdoMet
synthetase activity of P. carinii can be no more than 0.1%
of that of rat liver, and we conclude that P. carinii has no
AdoMet synthetase activity. We can eliminate the remote possibility that some AdoMet was produced by the P. carinii lysate but
consumed by other reactions, therefore not detected. Such reactions
would be either decarboxylation by AdoMet decarboxylase or loss of the radiolabeled methyl group by a methylation reaction. For the case of
decarboxylation, the HPLC conditions used would have produced a peak of
radioactivity at the retention time of 25 min but there was none (data
not shown). Decarboxylated AdoMet cannot be metabolized further because
dialysis removes the required aminopropyl acceptors. For the case of
methylation reactions, small molecule methyl receptors were removed by
dialysis of the extract. Large molecule methyl receptors would most
likely have been precipitated by perchloric acid at the final 10%
concentration and a check of the precipitate revealed no radioactivity.
If large molecules were not precipitated, they would have remained in
the extract applied to the HPLC column but the only radioactivity peaks
were accounted for by the commercially supplied radiolabeled
methionine. Extensive washing of the column eluted no additional
radioactivity.

View larger version (25K):
[in a new window]
Fig. 5.
AdoMet synthetase activity in P. carinii. The top panel presents an
radiolabel-based analysis of AdoMet present in an aliquot from a 30-min
assay for AdoMet synthetase in a P. carinii homogenate. No
AdoMet was detected. The bottom panel is an assay of another
aliquot from the same assay except 20 pmol of radiolabeled AdoMet was
added. The size of the 20-pmol peak demonstrates that as little as 0.5 pmol of AdoMet would have been easily detectable. These data indicate
that P. carinii has no AdoMet synthetase activity.

View larger version (8K):
[in a new window]
Fig. 6.
AdoMet concentration in rat plasma versus PCP
infection in the lungs. Rats with greater numbers of P. carinii in the lungs had markedly less AdoMet in their plasma.
This decline in plasma AdoMet demonstrates that in vitro
observations of exogenous AdoMet utilization by P. carinii
are relevant in vivo.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 of medium at 12 h, somewhat less than
reported AdoMet concentration in rat lungs, 11.1 µg g
1
of tissue (23). One could speculate that the now popular use of AdoMet
as a nutritional supplement could result in increased vulnerability to
infection with P. carinii but there is no direct data to
support this.
| |
FOOTNOTES |
|---|
* This work was supported in part by United States Public Health Service Grants R01 AI41947 and R01 AI43757.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Medical and
Molecular Parasitology, New York University School of Medicine, 341 East 25th St., New York, NY 10010. Tel.: 212-263-6956; Fax:
212-263-6956; E-mail: merals01@popmail.med.nyu.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: PCP, Pneumocystis carinii pneumonia; HIV, human immunodeficiency virus; AdoMet, S-adenosyl-L-methionine; HPLC, high performance liquid chromatography.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Wilkin, A., and Feinberg, J. (1999) Am. Fam. Physician 60, 1699-1708[Medline] [Order article via Infotrieve], 1713-1714 |
| 2. |
Azoulay, E.,
Parrot, A.,
Flahault, A.,
Cesari, D.,
Lecomte, I.,
Roux, P.,
Saidi, F.,
Fartoukh, M.,
Bernaudin, J. F.,
Cadranel, J.,
and Mayaud, C.
(1999)
Am. J. Respir. Crit. Care Med.
160,
493-499 |
| 3. | Cohen, S. (1998) A Guide to Polyamines , Oxford University Press, Oxford |
| 4. |
Newman, E. B.,
Budman, L. I.,
Chan, E. C.,
Greene, R. C.,
Lin, R. T.,
Woldringh, C. L.,
and D'Ari, R.
(1998)
J. Bacteriol.
180,
3614-3619 |
| 5. | Cherest, H., Sudin-Kerjan, Y., Exinger, F., and Lacroute, F. (1978) Mol. Gen. Genet. 163, 153-167[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Brawley, J. V.,
and Ferro, A. J.
(1980)
J. Bacteriol.
142,
608-614 |
| 7. | Duce, A. M., Ortiz, P., Cabrero, C., and Mato, J. M. (1988) Hepatology 8, 65-68[Medline] [Order article via Infotrieve] |
| 8. | Pisi, E., and Marchesini, G. (1990) Drugs 40 Suppl. 3, 65-72 |
| 9. |
Merali, S.,
Frevert, U.,
Williams, J. H.,
Chin, K.,
Bryan, R.,
and Clarkson, A. B.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2402-2407 |
| 10. | Merali, S., and Clarkson, A. B., Jr. (1996) Antimicrob. Agents Chemother. 40, 973-978[Abstract] |
| 11. | Merali, S., Chin, K., Grady, R. W., Weissberger, L., and Clarkson, A. B., Jr. (1995) Antimicrob. Agents Chemother. 39, 1442-1444[Abstract] |
| 12. | Merali, S., Chin, K., Del Angel, L., Grady, R. W., Armstrong, M., and Clarkson, A. B., Jr. (1995) Antimicrob. Agents Chemother. 39, 2023-2026[Abstract] |
| 13. | Le Quesne, S., and Fairlamb, A. (1998) in Polyamine Protocols (Morgan, D., ed), Vol. 79 , pp. 149-156, Humana Press, Totowa, NJ |
| 14. | Merali, S., and Clarkson, A. B., Jr. (1996) J. Chromatogr. Sect. B Biomed. Appl. 675, 321-326 |
| 15. |
Merali, S.
(1999)
J. Biol. Chem.
274,
21017-21022 |
| 16. | Yarlett, N., Garofalo, J., Goldberg, B., Ciminelli, M. A., Ruggiero, V., Sufrin, J. R., and Bacchi, C. J. (1993) Biochim. Biophys. Acta 1181, 68-76[Medline] [Order article via Infotrieve] |
| 17. | Parks, L., and Schlenk, F. (1957) J. Biol. Chem. 230, 295-305 |
| 18. |
Rouillon, A.,
Surdin-Kerjan, Y.,
and Thomas, D.
(1999)
J. Biol. Chem.
274,
28096-28105 |
| 19. | Corrales, F., Ochoa, P., Rivas, C., Martin-Lomas, M., Mato, J. M., and Pajares, M. A. (1991) Hepatology 14, 528-533[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Chin, K., Merali, S., Saric, M., and Clarkson, A. B., Jr. (1996) Antimicrob. Agents Chemother. 40, 2318-2320[Abstract] |
| 21. |
Saric, M.,
and Clarkson, A. B., Jr.
(1994)
Antimicrob. Agents Chemother.
38,
2545-2552 |
| 22. | Sloand, E., Laughon, B., Armstrong, M., Bartlett, M. S., Blumenfeld, W., Cushion, M., Kalica, A., Kovacs, J. A., Martin, W., Pitt, E., Pesanti, E. D., Richards, F., Rose, R., and Walzcr, P. (1993) J. Eukaryotic Microbiol. 40, 188-195[Medline] [Order article via Infotrieve] |
| 23. | Baldessarini, R. J., and Kopin, I. J. (1966) J. Neurochem. 13, 769-777[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Murphy, J. T.,
and Spence, K. D.
(1972)
J. Bacteriol.
109,
499-504 |
| 25. | Goldberg, B., Yarlett, N., Sufrin, J., Lloyd, D., and Bacchi, C. J. (1997) FASEB J. 11, 256-260[Abstract] |
| 26. | Bontemps, F., and Van Den Berghe, G. (1997) Biochem. J. 327, 383-389 |
| 27. | McIntosh, L. (1994) Plant Physiol. 105, 781-786[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Goldberg, B., Rattendi, D., Lloyd, D., Sufrin, J. R., and Bacchi, C. J. (1998) Biochem. Pharmacol. 56, 95-103[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
C. A. Moncada, A. Clarkson, O. Perez-leal, and S. Merali Mechanism and Tissue Specificity of Nicotine-mediated Lung S-Adenosylmethionine Reduction J. Biol. Chem., March 21, 2008; 283(12): 7690 - 7696. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kutty, B. Hernandez-Novoa, M. Czapiga, and J. A. Kovacs Pneumocystis Encodes a Functional S-Adenosylmethionine Synthetase Gene Eukaryot. Cell, February 1, 2008; 7(2): 258 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zheng, S. Shuman, and B. Schwer Sinefungin resistance of Saccharomyces cerevisiae arising from sam3 mutations that inactivate the AdoMet transporter or from increased expression of AdoMet synthase plus mRNA cap guanine-N7 methyltransferase Nucleic Acids Res., November 29, 2007; 35(20): 6895 - 6903. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Greenberg, B. Rimal, K. Felner, S. Zafar, J. Hung, E. Eylers, B. Phalan, M. Zhang, J. D. Goldberg, B. Crawford, et al. S-Adenosylmethionine as a Biomarker for the Early Detection of Lung Cancer Chest, October 1, 2007; 132(4): 1247 - 1252. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shivji, S. Burger, C. A. Moncada, A. B. Clarkson Jr., and S. Merali Effect of Nicotine on Lung S-Adenosylmethionine and Development of Pneumocystis Pneumonia J. Biol. Chem., April 15, 2005; 280(15): 15219 - 15228. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Song, S. Barve, T. Chen, W. Nelson, S. Uriarte, D. Hill, and C. McClain S-adenosylmethionine (AdoMet) modulates endotoxin stimulated interleukin-10 production in monocytes Am J Physiol Gastrointest Liver Physiol, June 1, 2003; 284(6): G949 - G955. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Tucker, H. H. Winkler, L. O. Driskell, and D. O. Wood S-Adenosylmethionine Transport in Rickettsia prowazekii J. Bacteriol., May 15, 2003; 185(10): 3031 - 3035. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Larsen, J. A. Kovacs, F. Stock, V. H. Vestereng, B. Lundgren, S. H. Fischer, and V. J. Gill Development of a Rapid Real-Time PCR Assay for Quantitation of Pneumocystis carinii f. sp. carinii J. Clin. Microbiol., August 1, 2002; 40(8): 2989 - 2993. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals< |